{
  "docId": "019de074-704c-735b-b7a3-613838aa1bf3",
  "docSlug": "9b81d8a09c69afc3f139dc970effabde",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 39,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Includes footnotes detailing cash equivalents and share breakdown.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/26",
  "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3",
  "deckJsonHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3.json",
  "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.035,
        "w": 0.416,
        "x": 0.292,
        "y": 0.805
      },
      "kind": "callout",
      "text": "Expected funding runway: into fourth quarter of 2023",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fb7a384-0283-436a-b224-e65074f01f79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.71,
        "x": 0.068,
        "y": 0.178
      },
      "kind": "paragraph",
      "text": "Cash and available funds as of December 31, 2022: $57.3¹ million (no debt)\nAs of February 21, 2023, 94.3 million² common shares and pre-funded warrants outstanding",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65147241-5f0c-45ae-963a-413ecc015a5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.688,
        "x": 0.06,
        "y": 0.915
      },
      "kind": "source-note",
      "text": "¹ Includes cash, cash equivalents, marketable securities and restricted cash. ²Includes 65.4 million common shares outstanding and 28.9 million pre-funded warrants.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82c6c5f4-e290-44da-a102-b50461a714d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.66,
        "x": 0.17,
        "y": 0.404
      },
      "kind": "table",
      "text": "Revenue, R&D Expense, G&A Expense, Net Loss for 2022 and 2021",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b6d2fb4-afe4-4e61-b074-616e159b4373",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.299,
        "x": 0.068,
        "y": 0.038
      },
      "kind": "title",
      "text": "Financial Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7b318ca-559e-461b-a4d9-b00e60da72b0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "feec764f-f9c2-45c1-b28d-ae36259c622a",
      "evidence": "Revenue, R&D Expense, G&A Expense, Net Loss for 2022 and 2021",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 26,
      "from": 25,
      "beatId": "ee42496b-f81a-4970-8acd-44ab2cd043a3",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact and Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document highlights the impact of Aeglea BioTherapeutics' therapies and outlines next steps for the company.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}